Showing 7321-7330 of 9077 results for "".
- JAK Kinase Inhibitors Show Promise in Treating Alopeciahttps://practicaldermatology.com/news/jak-kinase-inhibitors-show-promise-in-treating-alopecia/2459947/UPDATED -- New research suggests selective oral JAK kinase inhibitors may play a role in treating moderate-to-severe alopecia areata (AA). The findings were presented at the Inflammatory Skin Disease Summit in Vienna, Austria. In this
- Suneva Grows Their Aesthetics Portfolio with New Dealshttps://practicaldermatology.com/news/suneva-grows-their-aesthetics-portfolio-with-new-deals/2459946/Suneva® Medical, Inc., is partnering with Healeon Medical, Inc and Puregraft, LLC to add two new products to their a
- Glenmark Pharmaceuticals Enters US Branded Dermatology Segmenthttps://practicaldermatology.com/news/glenmark-pharmaceuticals-enters-us-branded-dermatology-segment/2457537/Glenmark Pharmaceuticals is entering into the branded dermatology segment in the United States. The branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc., USA, a wholly owned subsidiary of Glenmark Holding, SA. This represents an imp
- National Rosacea Society: New Grants Available in 2019https://practicaldermatology.com/news/national-rosacea-society-new-grants-available-in-2019/2457536/The National Rosacea Society (NRS) has new grants available in 2019 to support research into potential causes and other key aspects of rosacea that may lead to improvements in its management, prevention, or potential cure. The deadline for submitting proposals for research grants in 2019 is
- New Study Investigates Prurigo Nodularis Treatmentshttps://practicaldermatology.com/news/new-study-investigates-prurigo-nodularis-treatments/2457542/Emerging treatments such as neurokinin-1 receptor antagonists show the most promise for prurigo nodularis, according to a review in JAMA Dermatology. Neurokinin-1 receptor is a target of substance P, a medi
- AD, Suicidal Thoughts and Attempts Linkedhttps://practicaldermatology.com/news/ad-suicidal-thoughts-and-attempts-linked/2457543/Patients with eczema may be more likely to have suicidal thoughts and attempts compared to their counterparts without eczema, according to a new study in JAMA Dermatology. Res
- Case Study: Whole Body Cryotherapy Causes Cold Burn Injuryhttps://practicaldermatology.com/news/case-study-whole-body-cryotherapy-causes-cold-burn-injury/2457547/A 71-year-old man experienced a blistering cold burn after receiving a whole-body cryotherapy treatment for back pain and arthritis, according to a
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- New Xeomin "Later Haters" Campaign Urges Women to “X” Out Judgmenthttps://practicaldermatology.com/news/new-xeomin-later-haters-campaign-aims-to-x-out-judgment/2457487/Merz Americas is launching a new advertising campaign for Xeomin (incobotulinumtoxinA) called “Later Haters,” which urges women to “X out” judgment, stop apologizing for caring about how they look and put an end to f
- Phase 3 Data Positive for Revance's RT002https://practicaldermatology.com/news/phase-3-data-positive-for-revances-rt002/2457489/Long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term safety study. Completion of this study paves the way for Revance Therapeutics, Inc. to subm